Has Neuralink or xAI announced any projects targeting bladder control or incontinence?

1. What Neuralink publicly says it’s building — and what that implies

Neuralink’s stated mission and trial activity center on generalized brain–computer interfaces to restore autonomy for people with unmet medical needs, with concrete near-term work framed around enabling people with paralysis to control devices, restoring vision (Blindsight), and scaling human implants through the PRIME study; these are the uses most frequently mentioned in company pages and journalism ^{[6] [3] [2]}. That focus explains why most reporting frames Neuralink as working on motor-control decoding and sensory restoration rather than autonomic functions such as urinary continence ^{[1] [7]}.

2. The public clinical-trial record does not list bladder or incontinence targets

Neuralink’s clinical-trial notices and reporting describe recruitment of people with paralysis, spinal cord injury and neurodegenerative conditions and discuss Telepathy and Blindsight products; news outlets summarizing trial enrollment and company updates (PRIME study, Telepathy implants, Blindsight) do not list bladder-control as a named indication in available coverage ^{[3] [8] [2]}. Therefore, current public trial material does not show a discrete, announced program for urinary incontinence.

3. Why bladder control is plausible scientifically — but absent in current announcements

Restoring autonomic functions (bladder, bowel, blood pressure) is an active area in neurotechnology broadly, and restoring motor and sensory pathways can conceptually be extended to autonomic circuits. However, all coverage of Neuralink’s roadmap emphasizes motor intention decoding, vision restoration, and device control first — likely because those use cases map more directly to the company’s electrode-and-decoding approach and to regulatory pathways ^{[6] [2]}. News and company updates do not claim ongoing bladder-specific trials ^{[1] [3]}.

4. What reporting about xAI shows — and what it doesn’t

xAI, Elon Musk’s AI venture, is covered in these results largely in the context of fundraising, model development (Grok) and integration across Musk’s portfolio; Reuters and other outlets talk about Morgan Stanley debt raises and Colossus datacentre plans for xAI but do not connect xAI to medical-device projects or bladder-control research ^{[4] [8] [5]}. Available sources do not mention xAI announcing any programs to treat incontinence.

5. Competing perspectives and hidden agendas to watch for

Mainstream coverage (Reuters, MIT Technology Review, BBC) highlights Neuralink’s clinical milestones and fundraising; some outlets are promotional about “restoring autonomy” while others stress controversy and skepticism about risks and animal-testing issues — an implicit tension between PR and scrutiny in reporting ^{[8] [3] [9]}. Fundraising stories that link Neuralink and xAI (and note xAI’s big capital plans) can create a perception that all Musk ventures are tightly coordinated; sources reporting financings may have market or readership incentives to amplify scale, so interpret expansion claims within those contexts ^{[4] [10]}.

6. Bottom line and limitations of available reporting

There is no explicit, sourced announcement in the provided reporting that Neuralink or xAI have launched projects specifically targeting bladder control or urinary incontinence; published trial descriptions and media summaries list paralysis, vision restoration, motor control and neurodegenerative conditions instead ^{[3] [1] [2]}. If you are looking for a direct program targeting bladder function, available sources do not mention such a project.